Abstract
Background: Faecal calprotectin (FC) has proven its utility as a non-invasive marker for neutrophilic intestinal inflammation. It can be used in the differential diagnosis between functional and organic bowel disease. In Crohn’s disease and ulcerative colitis, FC is a very useful biomarker as it correlates with endoscopic disease activity. The objective of this study is to evaluate the recently launched quantitative immunochromatographic point of care tests (POCT) (Quantum Blue Calprotectin, Buhlmann Laboratories AG) to the currently used ELISA method (Buhlmann Laboratories AG) both numerically and regarding its reliability in distinguishing functional from organic bowel disease. Methods: 142 samples were analysed both with the ELISA and the POCT (normal range (30 300mg/g faeces) or high range (10
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call